Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells

References

• Chen W, Zheng R, Zeng H, Zhang S. Epidemiology of lung cancer in China. Thorac Cancer. 2015;6(2):209–15. doi:10.1111/1759-7714.12169
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54. doi:10.1038/nature25183
   PubMed Web of Science ®Google Scholar
• Pignon J-P, Tribodet H, Scagliotti GV, Douillard J-Y, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–9. doi:10.1200/JCO.2007.13.9030
   PubMed Web of Science ®Google Scholar
• Koberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta. 2010;1806(2):172–82. doi:10.1016/j.bbcan.2010.07.004
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83. doi:10.1038/onc.2011.384
   PubMed Web of Science ®Google Scholar
• Ferreira JA, Peixoto A, Neves M, Gaiteiro C, Reis CA, Assaraf YG, Santos LL. Mechanisms of cisplatin resistance and targeting of cancer stem cells: adding glycosylation to the equation. Drug Resist Updates. 2016;24:34–54. doi:10.1016/j.drup.2015.11.003
   PubMed Web of Science ®Google Scholar
• Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine . 2012;7(4):597–615. doi:10.2217/nnm.12.22
   PubMed Web of Science ®Google Scholar
• Schatton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays. 2009;31(10):1038–49. doi:10.1002/bies.200900058
   PubMed Web of Science ®Google Scholar
• Liu Y-P, Yang C-J, Huang M-S, Yeh C-T, Wu ATH, Lee Y-C, Lai T-C, Lee C-H, Hsiao Y-W, Lu J, et al. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res. 2013;73(1):406–16. doi:10.1158/0008-5472.CAN-12-1733
   PubMed Web of Science ®Google Scholar
• Ahmed EM, Bandopadhyay G, Coyle B, Grabowska A. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Cell Oncol (Dordr). 2018;41(3):319–28. doi:10.1007/s13402-018-0374-8
   PubMed Web of Science ®Google Scholar
• Li Y, Yang B, Bai J-Y, Xia S, Mao M, Li X, Li N, Chen L. The roles of synovial hyperplasia, angiogenesis and osteoclastogenesis in the protective effect of apigenin on collagen-induced arthritis. Int Immunopharmacol. 2019;73:362–9. doi:10.1016/j.intimp.2019.05.024
   PubMed Web of Science ®Google Scholar
• Hwang YP, Oh KN, Yun HJ, Jeong HG. The flavonoids apigenin and luteolin suppress ultraviolet A-induced matrix metalloproteinase-1 expression via MAPKs and AP-1-dependent signaling in HaCaT cells. J Dermatol Sci. 2011;61(1):23–31. doi:10.1016/j.jdermsci.2010.10.016
   PubMed Web of Science ®Google Scholar
• Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC, Pelling JC. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinog. 2008;47(9):686–700. doi:10.1002/mc.20421
   PubMed Web of Science ®Google Scholar
• Lindenmeyer F, Li H, Menashi S, Soria C, Lu H. Apigenin acts on the tumor cell invasion process and regulates protease production. Nutr Cancer. 2001;39(1):139–47. doi:10.1207/S15327914nc391_19
   PubMed Web of Science ®Google Scholar
• Li Y-W, Xu J, Zhu G-Y, Huang Z-J, Lu Y, Li X-Q, Wang N, Zhang F-X. Apigenin suppresses the stem cell-like properties of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. Cell Death Discov. 2018;4:105. doi:10.1038/s41420-018-0124-8
   PubMed Web of Science ®Google Scholar
• Ketkaew Y, Osathanon T, Pavasant P, Sooampon S. Apigenin inhibited hypoxia induced stem cell marker expression in a head and neck squamous cell carcinoma cell line. Arch Oral Biol. 2017;74:69–74. doi:10.1016/j.archoralbio.2016.11.010
   PubMed Web of Science ®Google Scholar
• Lu H-F, Chie Y-J, Yang M-S, Lu K-W, Fu J-J, Yang J-S, Chen H-Y, Hsia T-C, Ma C-Y, Ip S-W, et al. Apigenin induces apoptosis in human lung cancer H460 cells through caspase- and mitochondria-dependent pathways. Hum Exp Toxicol. 2011;30(8):1053–61. doi:10.1177/0960327110386258
   PubMed Web of Science ®Google Scholar
• Liu R, Ji P, Liu B, Qiao H, Wang X, Zhou L, Deng T, Ba Y. Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis. Oncol Lett. 2017;13(2):1024–30. doi:10.3892/ol.2016.5495
   PubMed Web of Science ®Google Scholar
• Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ, O'Byrne KJ, et al. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One. 2013;8(1):e54193. doi:10.1371/journal.pone.0054193
   PubMed Web of Science ®Google Scholar
• Liu B, Yang P, Ye Y, Zhou Y, Li L, Tashiro S-I, Onodera S, Ikejima T. Role of ROS in the protective effect of silibinin on sodium nitroprusside-induced apoptosis in rat pheochromocytoma PC12 cells. Free Radic Res. 2011;45(7):835–47. doi:10.3109/10715762.2011.580343
   PubMed Web of Science ®Google Scholar
• Park EK, Lee JC, Park JW, Bang SY, Yi SA, Kim BK, Park JH, Kwon SH, You JS, Nam SW, et al. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Cell Death Dis. 2015;6:e1964. doi:10.1038/cddis.2015.313
   PubMed Web of Science ®Google Scholar
• Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans. 2001;29(Pt 6):684–8. doi:10.1042/0300-5127:0290684
   PubMed Web of Science ®Google Scholar
• Shukla S, Bhaskaran N, Babcook MA, Fu P, MacLennan GT, Gupta S. Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. Carcinogenesis. 2014;35(2):452–60. doi:10.1093/carcin/bgt316
   PubMed Web of Science ®Google Scholar
• Masuelli L, Benvenuto M, Mattera R, Di Stefano E, Zago E, Taffera G, Tresoldi I, Giganti MG, Frajese GV, Berardi G, et al. In vitro and in vivo anti-tumoral effects of the flavonoid apigenin in malignant mesothelioma. Front Pharmacol. 2017;8:373 doi:10.3389/fphar.2017.00373
   PubMed Web of Science ®Google Scholar
• Guntur VP, Waldrep JC, Guo JJ, Selting K, Dhand R. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res. 2010;30:3557–64.
   PubMed Web of Science ®Google Scholar
• Shang L, Wei M. Inhibition of SMYD2 sensitized cisplatin to resistant cells in NSCLC through activating p53 pathway. Front Oncol. 2019;9:306. doi:10.3389/fonc.2019.00306
   PubMed Web of Science ®Google Scholar
• Ouyang DY, Wang YY, Zheng YT. Activation of c-Jun N-terminal kinases by ribotoxic stresses. Cell Mol Immunol. 2005;2(6):419–25.
   PubMed Web of Science ®Google Scholar
• Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene. 2008;27(48):6245–51. doi:10.1038/onc.2008.301
   PubMed Web of Science ®Google Scholar
• Chen M, Wang X, Zha D, Cai F, Zhang W, He Y, Huang Q, Zhuang H, Hua Z-C. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner. Sci Rep. 2016;6(1):35468. doi:10.1038/srep35468
   PubMed Web of Science ®Google Scholar
• Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol. 2008;9(12):1004–10. doi:10.1038/nrm2529
   PubMed Web of Science ®Google Scholar
• Cao X, Liu B, Cao W, Zhang W, Zhang F, Zhao H, Meng R, Zhang L, Niu R, Hao X, et al. Autophagy inhibition enhances apigenin-induced apoptosis in human breast cancer cells. Chin J Cancer Res. 2013;25(2):212–22. doi:10.3978/j.issn.1000-9604.2013.04.01
   PubMed Web of Science ®Google Scholar
• Hao C, Liu G, Tian G. Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma. Ther Adv Respir Dis. 2019;13:1753466619866097. doi:10.1177/1753466619866097
   Web of Science ®Google Scholar
• Jerry DJ, Tao L, Yan H. Regulation of cancer stem cells by p53. Breast Cancer Res. 2008;10(4):304. doi:10.1186/bcr2133
   PubMed Web of Science ®Google Scholar
• Deshmukh A, Deshpande K, Arfuso F, Newsholme P, Dharmarajan A. Cancer stem cell metabolism: a potential target for cancer therapy. Mol Cancer. 2016;15(1):69. doi:10.1186/s12943-016-0555-x
   PubMed Web of Science ®Google Scholar
• Phi LTH, Sari IN, Yang Y-G, Lee S-H, Jun N, Kim KS, Lee YK, Kwon HY. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018;2018:5416923. doi:10.1155/2018/5416923
   PubMed Web of Science ®Google Scholar
• Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9(5):402–12. doi:10.1038/nrm2395
   PubMed Web of Science ®Google Scholar
• Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell. 2008;134(1):62–73. doi:10.1016/j.cell.2008.06.006
   PubMed Web of Science ®Google Scholar
• Wang Z, Oron E, Nelson B, Razis S, Ivanova N. Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell. 2012;10(4):440–54. doi:10.1016/j.stem.2012.02.016
   PubMed Web of Science ®Google Scholar
• Liu A, Yu X, Liu S. Pluripotency transcription factors and cancer stem cells: small genes make a big difference. Chin J Cancer. 2013;32(9):483–7. doi:10.5732/cjc.012.10282
   PubMedGoogle Scholar
• Song W-S, Yang Y-P, Huang C-S, Lu K-H, Liu W-H, Wu W-W, Lee Y-Y, Lo W-L, Lee S-D, Chen Y-W, et al. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. J Chin Med Assoc. 2016;79(10):538–45. doi:10.1016/j.jcma.2016.03.010
   PubMed Web of Science ®Google Scholar
• Chen B, Zhu Z, Li L, Ye W, Zeng J, Gao J, Wang S, Zhang L, Huang Z. Effect of overexpression of Oct4 and Sox2 genes on the biological and oncological characteristics of gastric cancer cells. Onco Targets Ther. 2019;12:4667–82. doi:10.2147/OTT.S209734
   PubMed Web of Science ®Google Scholar